Ningbo Meishan Xinaishan Equity Investment

Ningbo Meishan Xinaishan Equity Investment Limited Partnership is a Chinese private equity fund focused on the healthcare and life sciences sectors. Established in November 2020 and based in Ningbo, the partnership serves as a strategic investment vehicle for its partners, most notably the Nasdaq-listed healthcare services provider Zhongchao Inc. (ZCMD). The fund's primary mandate is to identify and invest in high-growth private Chinese companies specializing in innovative medical technologies, with a specific emphasis on immunotherapy and oncology. Its core portfolio consists of a strategic investment in a private immunotherapy firm, reflecting the broader commitment of its stakeholders to advancing cancer treatment and patient management solutions in the Chinese market. The partnership's operational term was recently extended through November 2028 to continue its investment activities.